Status:

COMPLETED

Compliance With Once-Daily Divalproex Extended-Release Tablets (Depakote-ER) Versus Multiple-Daily Dose Valproic Acid Capsules (Depakene) in Epilepsy:

Lead Sponsor:

Orlando Health, Inc.

Collaborating Sponsors:

Abbott

Conditions:

Epilepsy

Eligibility:

All Genders

16-99 years

Brief Summary

To determine, in a randomized, parallel open-label fashion, compliance rates between once-daily extended-release divalproex sodium tablets (Depakote-ER®, Abbott Labs) versus multiple-daily dose valpro...

Detailed Description

x\_ Prospective x\_\_ Single-center \_\_ Multicenter x\_\_ Open-label \_\_ Double-blind \_\_ Single-blind x\_ Randomized (please provide randomization ratio): 1:1 This population includes both patient...

Eligibility Criteria

Inclusion

  • 1) Patients, age 16 and above, currently taking Divalproex-DR for any seizure disorder; 2) Other AEDs are permitted concurrently, although compliance with these will not be recorded. Other medications for co-morbid disease are permitted, provided no plans for changes in medications used for the treatment of the concomitant disorder are expected.
  • 3\) Patients must demonstrate a 75% or greater compliance rate with DR via calendar during the week of familiarity with the MEMs unit. The threshold value of 75% has been chosen since research shows that people take approximately 75% of their AED(s) as prescribed (13,14), and the same numerical value is frequently used in determining whether or not to retain a patient in clinical Phase 2a-3b industry-sponsored study.
  • \-

Exclusion

  • 1) patients with a recent history of status epilepticus; 2) patients who have refractory or unstable epilepsy; 3) patients with acute illnesses requiring changes in concurrent drugs; 4) patients unwilling to change from their present DR regimen to divalproex-ER or IR-VPA.
  • 5\) Patients unwilling or unable to utilize the MEMs monitoring unit; 6) Pregnant or lactating women.
  • \-

Key Trial Info

Start Date :

July 1 2006

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

May 1 2007

Estimated Enrollment :

5 Patients enrolled

Trial Details

Trial ID

NCT00356018

Start Date

July 1 2006

End Date

May 1 2007

Last Update

March 4 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Orlando Regional Lucerne Hospital

Orlando, Florida, United States, 32801